Abstract 1198P
Background
RYZ101 (225Ac-DOTATATE) is an alpha-emitting radiopharmaceutical in development for SSTR2+ solid tumors. Alpha-particles have a shorter path length/higher linear energy transfer than beta-particles, causing more frequent double-strand DNA breaks and potentially improved therapeutic index. ACTION-1 (NCT05477576) is a 2-part, global, randomized, controlled, open-label, phase 1b/3 trial of RYZ101 in advanced, well-differentiated SSTR+ GEP-NETs progressing after 177Lu-SSA therapy. Herein, we report results from the phase Ib portion of the trial.
Methods
The phase Ib portion had a dose de-escalation/Bayesian optimal interval design with boundaries based on a dose-limiting toxicity (DLT) rate of 25%. Patients (pts) received RYZ101 IV q8w x4 cycles. Planned dose levels (n=6/level): Level 0 (starting dose) 120kBq/kg; Level –1 90kBq/kg; Level –2 60kBq/kg. DLT was assessed for 56d after the first RYZ101 dose. Treatment-emergent adverse events (TEAEs) were graded by NCI-CTCAE v5.0. Dose de-escalation decisions/safety data were overseen by a Data Review Committee. Tumor response was assessed locally by RECIST v1.1.
Results
17 pts have received at least one dose of RYZ101 at 120kBq/kg (4 doses: 6 pts; 3 doses: 2 pts; 2 doses: 8 pts; 1 dose: 1 pt; median 8.9MBq). Baseline characteristics: median age 63y; male (n=11); ECOG PS 0/1 (n=10/7); primary tumor site GI/pancreas (n=12/5). No DLTs, no dose de-escalation and no treatment-related serious AEs (SAEs) occurred. TEAEs requiring dose reductions occurred in 2 pts (G2 thrombocytopenia, n=2). G3/4 TEAEs occurred in 6 pts, 3 related to RYZ101 (lymphopenia, n=2; weight decreased, n=1). SAEs occurred in 4 pts (all unrelated). Confirmed objective response was seen in 5 evaluable pts. Updated efficacy data will be provided at the congress.
Conclusions
RYZ101 was well tolerated and a fixed dose of 10.2MBq was declared the recommended phase 3 dose. Initial data suggest promising efficacy. Part 2 (phase 3) is enrolling and will compare RYZ101 at 10.2MBq q8w for 4 cycles with standard of care in pts with advanced SSTR2+ GEP-NETs progressing following prior 177Lu-labeled SSAs.
Clinical trial identification
ACTION-1 (NCT05477576).
Editorial acknowledgement
Editorial assistance for this abstract was provided by Lee Miller (Miller Medical Communications Ltd). This work was funded by the study sponsor (RayzeBio Inc).
Legal entity responsible for the study
RayzeBio Inc.
Funding
RayzeBio Inc.
Disclosure
J. Strosberg: Financial Interests, Personal, Speaker’s Bureau: Ipsen; Financial Interests, Personal, Advisory Board: Novartis, Tersera; Financial Interests, Institutional, Principal Investigator: Merck, Novartis, Alphamedix; Financial Interests, Personal, Advisory Role: Novartis. G. Ulaner: Financial Interests, Personal, Speaker’s Bureau: GE Healthcare, Lantheus; Financial Interests, Institutional, Research Grant: GE Healthcare, Lantheus, Nuclidium, Curium, RayzeBio, ImmaginAb, BriaCell, POINT; Financial Interests, Personal, Advisory Role: GE Healthcare, Lantheus, Nuclidium, POINT. H.P. Soares: Financial Interests, Personal, Advisory Board: TerSera, Ipsen, AstraZeneca, Novartis, ITM. L.B. Anthony: Financial Interests, Institutional, Principal Investigator: Rayzebio. H. Jacene: Financial Interests, Personal, Invited Speaker: Monrol, ITM; Financial Interests, Personal, Member of Board of Directors: SNMMI; Financial Interests, Personal, Royalties: Cambridge University Press; Financial Interests, Institutional, Funding: Blue Earth Diagnostics; Financial Interests, Personal, Speaker, Consultant, Advisor: Blue Earth Diagnostics, Spectrum Dynamics. D. Ferreira: Financial Interests, Personal, Full or part-time Employment: RayzeBio, Bayer; Financial Interests, Personal, Stocks or ownership: RayzeBio, Bayer, Medtronic. J. Li: Financial Interests, Personal, Full or part-time Employment: RayzeBio; Financial Interests, Personal, Stocks or ownership: RayzeBio. K. Ma: Financial Interests, Personal, Full or part-time Employment: RayzeBio; Financial Interests, Personal, Stocks or ownership: RayzeBio. J. Rearden: Financial Interests, Personal, Stocks or ownership: RayzeBio; Financial Interests, Personal, Full or part-time Employment: RayzeBio. S. Moran: Financial Interests, Personal, Full or part-time Employment: RayzeBio; Financial Interests, Personal, Stocks or ownership: RayzeBio. T. Hope: Financial Interests, Institutional, Research Funding: Clovis Oncology, Philips, GE Healthcare, Lantheus, Janssen, The Prostate Cancer Foundation, The National Cancer Institute; Financial Interests, Personal, Advisory Role: Ipsen, Bayer, BlueEarth Diagnostics, RayzeBio, Curium; Financial Interests, Personal, Stocks or ownership: RayzeBio, Curium. M. Morris: Financial Interests, Personal, Advisory Board: Gentem Health, Softhread; Financial Interests, Personal, Full or part-time Employment: AMIT; Financial Interests, Personal, Ownership Interest: AMIT, Gentem Health, Softhread; Financial Interests, Personal, Principal Investigator: AMIT; Financial Interests, Institutional, Proprietary Information: AMIT; Financial Interests, Institutional, Sponsor/Funding: AMIT. All other authors have declared no conflicts of interest.
Resources from the same session
1109P - Second-line pembrolizumab (pembro) in Chinese patients (pts) with advanced melanoma: Long-term follow-up of the phase I KEYNOTE-151 study
Presenter: Lu Si
Session: Poster session 13
1110P - A phase II clinical trial of SHR-1701 combined with temozolomide for advanced melanoma
Presenter: Tu Hu
Session: Poster session 13
1111P - A randomised phase II study of intermittent versus continuous dosing of targeted therapy in patients with BRAFV600 mutant advanced melanoma (INTERIM)
Presenter: Avinash Gupta
Session: Poster session 13
1112P - Five-year survival after intermittent targeted therapy and anti-PD1 in stage IV melanoma: An update of the IMPemBra trial
Presenter: Lotte Hoeijmakers
Session: Poster session 13
1113P - COLUMBUS 7-year update: A randomized, open-label, phase III trial of encorafenib (enco) + binimetinib (bini) vs vemurafenib (vemu) or enco in patients (pts) with BRAF V600–mutant melanoma
Presenter: Dirk Schadendorf
Session: Poster session 13
1114P - Encorafenib (E) plus binimetinib (B) in unresectable advanced or metastatic BRAFV600-mut melanoma, real-world evidence in Spain (GEM 2002 - BECARE)
Presenter: Ainara Soria Rivas
Session: Poster session 13
1115P - Comparison of efficacy and toxicity of dabrafenib/trametinib versus vemurafenib/cobimetinib therapy in routine medical practice: Eight years of BRAF/MEK inhibitor use in routine clinical practice
Presenter: Karolina Piejko
Session: Poster session 13
1116P - Long term outcome of complete responders to immune checkpoint inhibitors (ICI) or target therapy (TT) in advanced melanoma
Presenter: Celine Boutros
Session: Poster session 13
1117P - Overall survival (OS) in patients with metastatic BRAF V600-mutant melanoma treated with encorafenib plus binimetinib (ENCO+BINI): Comparing real-world vs clinical trial data
Presenter: Gino In
Session: Poster session 13
1118P - Real-world treatment patterns and outcomes among patients with BRAF+ metastatic melanoma refractory to first-line immunotherapy
Presenter: Thach-Giao Truong
Session: Poster session 13